Physician profile
Clement C Eiswirth
NPI 1477538726
$277,115.63
in general payments reported to CMS, 2019-2025
22 companies · $11K in 2025
The $11K reported for 2025 was more than what 78% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $30K · 2021: $26K · 2022: $54K · 2023: $75K · 2024: $3,932 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Consulting Fee: $16K · Travel and Lodging: $5,334 · Food and Beverage: $3,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,263.23 |
| Consulting Fee | $16,095.00 |
| Travel and Lodging | $5,334.27 |
| Food and Beverage | $3,446.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $86,903.39 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $67,243.64 | 2021-2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $61,397.99 | 2019-2025 | Onpattro |
| Akcea Therapeutics, INC. | $34,695.46 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $13,871.39 | 2019-2022 | |
| Bridgebio Pharma, INC. | $10,961.03 | 2025 | Attruby |
| Abbott Laboratories | $628.17 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Sirtex Medical INC | $512.65 | 2023-2025 | Sir-Spheres Microspheres |
| Abiomed | $184.61 | 2019-2023 | Impella |
| Cvrx, INC. | $176.24 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.98 | 2023 | Lifevest |
| Medtronic, INC. | $85.15 | 2022 | |
| United Therapeutics Corporation | $71.68 | 2021-2024 | |
| Actelion Pharmaceuticals US, INC. | $70.58 | 2022-2023 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals Lp | $61.53 | 2019-2023 | Farxiga |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $38.90 | 2024-2025 | |
| Edwards Lifesciences Corporation | $31.68 | 2022 | |
| Cardiac Dimensions, INC. | $23.79 | 2025 | |
| Novo Nordisk INC | $21.35 | 2024 | Ozempic |
| Amgen INC. | $15.41 | 2022 | |
| Livanova USA, INC. | $13.01 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clement Eiswirth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.